Cumberland Pharmaceuticals Inc. reported net revenues of $8.3 million for the third quarter of 2025 and $30.8 million for the first nine months of 2025, reflecting a 12% increase compared to the same period in 2024. Total operating expenses were $10.3 million for the third quarter and $32.3 million for the first nine months. The company recorded a net loss of approximately $1.9 million for the third quarter and a year-to-date net loss of about $1.4 million. Adjusted loss for the third quarter was $0.8 million, or $0.06 per share, while adjusted earnings for the first nine months were $1.9 million, or $0.13 per diluted share. As of September 30, 2025, Cumberland had total assets of $66 million, liabilities of $40 million, and shareholders' equity of $26 million, with $15 million in cash and cash equivalents. The company added a new FDA-approved brand to its commercial product portfolio during the period.